<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00809068</url>
  </required_header>
  <id_info>
    <org_study_id>ID: 2005-001</org_study_id>
    <secondary_id>SCGH Research Grant</secondary_id>
    <nct_id>NCT00809068</nct_id>
  </id_info>
  <brief_title>High-density Lipoprotein (HDL) Cholesterol in Women Taking Tibolone</brief_title>
  <acronym>TibFen</acronym>
  <official_title>Effects of Tibolone and PPARÎ±-agonist on HDL Metabolism in Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Keogh Institute for Medical Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Keogh Institute for Medical Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tibolone (Livial) has been shown in previous studies to lower HDL cholesterol by up to 40%.

      This study aims to study the effects of fenofibrate on HDL and subfractions in women taking
      tibolone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tibolone decreases plasma concentrations of HDL cholesterol and HDL-apoA1 and pre-beta HDL,
      consistent with a pro-atherogenic effect. The mechanism of tibolone on HDL cholesterol has
      been suggested to result from an acceleration of the catabolism of HDL by stimulation of
      hepatic lipase with no effect on cellular cholesterol efflux.

      PPAR-a agonists, in particular fenofibrate, improve HDL metabolism by increasing the
      expression and hepatic secretion of HDL apoAI and apoAII.

      We hypothesise that fenofibrate will rectify the perturbations on HDL metabolism wrought by
      tibolone.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HDL subpopulation analysis</measure>
    <time_frame>August 2009</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Increase in HDL subpopulations</measure>
    <time_frame>December 2009</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>HDL Cholesterol</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>fenofibrate and tibolone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>tibolone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fenofibrate and tibolone</intervention_name>
    <description>fenofibrate 160mg daily 8 weeks tibolone 2.5mg daily 23 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Lipidil</other_name>
    <other_name>Livial</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tibolone</intervention_name>
    <description>tibolone 2.5 mg daily 23 weeks</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Livial</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Post-menopausal women

          -  More than 6 months of amenorrhoea

          -  Raised FSH and low oestradiol level

          -  If hysterectomised, raised FSH and low oestradiol level

        Exclusion Criteria:

          -  Diabetes

          -  Renal failure

          -  Proteinuria

          -  High alcohol intake

          -  Regular endurance exercise

          -  Active weight loss of dieting

          -  Smokers

          -  Agents known to influence lipid metabolism

          -  Major systemic illness

          -  Intolerance to tibolone and fenofibrate

          -  Cholelithiasis

          -  CK and ALT &gt; 2ULN

          -  Bleeding disorders

          -  Peptic ulcer disease.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bronwyn G Stuckey, MBBS FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Keogh Institute for Medical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gerald F Watts, MD PhD FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>School pf Medicine and Pharmacology, Royal Perth Hospital.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rosalind Hampton, BSc MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Keogh Institute for Medical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hugh Barrett, BAgSc PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>School of Medicine and Pharmacology, Royal Perth Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Keogh Institute for Medical Research, 'A' Block 3rd Floor, QE II Medical Centre, Nedlands</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2008</study_first_submitted>
  <study_first_submitted_qc>December 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2008</study_first_posted>
  <last_update_submitted>January 31, 2010</last_update_submitted>
  <last_update_submitted_qc>January 31, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Clinical Professor Bronwyn Stuckey</name_title>
    <organization>Keogh Institute for Medical Research</organization>
  </responsible_party>
  <keyword>Menopause</keyword>
  <keyword>menopausal symptoms</keyword>
  <keyword>tibolone</keyword>
  <keyword>HDL-C</keyword>
  <keyword>fenofibrate</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenofibrate</mesh_term>
    <mesh_term>Tibolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

